1. Scrip
  2. >>Business
  3. >>Strategy

J.P. Morgan Day 1: Companies Make Deal-Making, COVID-19 Promises

Updates From Amgen, Gilead, Alnylam, Vertex, BioNTech, BioMarin, Merck KGAA

 
• By Scrip Team

Daily round-up from the virtual J.P. Morgan Healthcare Conference: Business development is key topic for Amgen and Vertex; BioNTech talks COVID-19 vaccine supply while Merck KGAA's new CEO pledges to rise to meet the challenges posed by COVID-19.

J.P. Morgan Daily Notebook - Day 1

Amgen, Inc. continues to be under pressure to generate new drugs from its labs and to engage in business development that can contribute significant revenue growth as several blockbuster products face ongoing competition from generics and biosimilars. And as expected during the question-and-answer portion of Amgen’s J.P. Morgan Healthcare Conference presentation, CEO Bob Bradway was asked about the company’s deal-making prospects this year. (Also see "Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs" - Scrip, 29 October, 2020.)

“We have a world-class business development effort,” Bradway said. “We are focused on finding opportunities to invest in our business...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

More from Business